Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.

[1]  N. Nagy,et al.  Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma , 2020, Genes.

[2]  S. Barrington,et al.  Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study , 2020 .

[3]  M. Calaminici,et al.  IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. , 2020, Blood.

[4]  D. Scott,et al.  Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma. , 2019, Blood.

[5]  A. López-Guillermo,et al.  Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population , 2019, British journal of haematology.

[6]  D. Rossi,et al.  Liquid biopsy in lymphoma , 2019, Haematologica.

[7]  Ash A. Alizadeh,et al.  Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Kimby,et al.  Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. , 2018, The Lancet. Haematology.

[9]  E. González-Barca,et al.  Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome , 2017, Hematological oncology.

[10]  R. Foà,et al.  Diffuse large B-cell lymphoma genotyping on the liquid biopsy. , 2017, Blood.

[11]  A Rosenwald,et al.  Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma , 2016, Leukemia.

[12]  L. Staudt,et al.  Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. , 2016, Blood.

[13]  E. Feuer,et al.  Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[14]  J. Friedberg,et al.  Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). , 2015, Blood.

[15]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Roland Schmitz,et al.  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.

[17]  Ash A. Alizadeh,et al.  Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. , 2015, Blood.

[18]  L. Staudt,et al.  Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. , 2015, The Lancet. Oncology.

[19]  H. Feilotter,et al.  Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome , 2014, Clinical Cancer Research.

[20]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[21]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[22]  J. Cerhan,et al.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Federico,et al.  The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[25]  I. Lossos,et al.  Transformation of follicular lymphoma. , 2011, Best practice & research. Clinical haematology.

[26]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.